ArticleCureus2025
Reversible Heart Failure After Anthracycline and Alkylating Agent Chemotherapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiotoxicity, including chemotherapy-induced heart failure (HF), remains a significant and well-recognised complication in modern oncologic practice. As cancer therapies evolve, treatment-related comorbidities continue to pose persistent challenges to patient outcomes and long-term survivorship. Among these, cytostatic-induced cardiotoxicity is particularly concerning due to its multifactorial and complex pathophysiology, involving oxidative stress, mitochondrial dysfunction, and direct myocardial injury. A comprehensive understanding of these mechanisms is essential for developing targeted preventive strategies and evidence-based therapeutic interventions. We report a case of a 41-year-old Caucasian female who developed chemotherapy-induced cardiomyopathy, or heart failure with reduced ejection fraction (HFrEF), following treatment for right-sided breast cancer. Baseline echocardiogram showed normal biventricular function; however, her left ventricular ejection fraction (LVEF) declined to 39% following dual anthracycline-based chemotherapy, specifically doxorubicin and cyclophosphamide, for breast cancer. The patient was subsequently managed with guideline-directed medical therapy (GDMT). At six- and 12-month follow-up, her LVEF improved to 45% and 50-55%, respectively, demonstrating favourable cardiac recovery under optimised pharmacologic management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.